News

B-701 is a new human monoclonal antibody specific for fibroblast growth factor receptor 3 (FGFR3) that is being developed to target FGFR3-positive tumors. The randomized, double-blinded, placebo-controlled, multicenter,

As part of the deal, MedImmune will have exclusive rights to Inovio’s INO-3112 immunotherapy, which targets cancers caused by human papillomavirus (HPV) types 16 and 18 that are

The multi-center Phase 1b trial enrolled 38 patients who were chemotherapy-naive, had unresectable MPM, had good performance status (ECOG 0 or 1), and adequate organ function. The company

The acquisition by Turing is part of a strategic effort focused on treatments for toxoplasmosis and other serious infectious diseases. The company also announced plans to invest in

The Phase I trials will evaluate the safety and efficacy of both investigative agents separately combined with an anti-PD-1 therapy Keytruda in these patients. Merck’s Keytruda is a

"SOMAmer molecules are a promising new class of drug entities, and we are excited to continue our work with SomaLogic to fully realize that promise," said Takayuki Shiratsuchi,

This randomized, dose-ranging trial is designed to evaluate three starting doses of ponatinib in patients with refractory, chronic-phase chronic myeloid leukemia (CP-CML) and is expected to inform the

Memantine Hydrochloride Tablets are equivalent to the branded product, Namenda, which is indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. "Approximately 5.3 million

The results from the multi-center, randomized Phase 2 trial showed that a single oral dose of SYM-1219 met the trial’s primary endpoint of Clinical Outcome Responder and was